Ottobock invests in innovative technologies from MIT start-ups

Ottobock is investing in innovative technologies for intuitive prosthesis control and digital socket technology with strategic ventures in the start-ups MuscleMetrix and BionicSkins. Ottobock is focusing on innovative cutting-edge technologies that enable people with mobility impairments to achieve far better and previously unimagined new mobility.

The investments in the two Massachusetts Institute of Technology (MIT) spin-offs founded by bionics pioneer Hugh Herr, underscore Ottobock's clear commitment to future-oriented product development and send a further signal for sustainable investment in modern medical technology.

Expertise

In addition to a financial investment in the millions, Ottobock is also investing its expertise in the two start-ups. As an investor and strategic partner, Ottobock will also take a seat on the board of both companies.

Oliver Jakobi, CEO of Ottobock SE & Co. KGaA says, "With these strategic investments, Ottobock is consistently expanding its innovation leadership. The technologies for prosthetics control with human-machine interface from MuscleMetrix represent an important building block for intuitive prosthesis control, bringing the movement patterns of users closer to natural human movement. BionicSkins sets new standards in digital and automated socket creation."

Intuitive control

MuscleMetrix offers a neuroprosthetic interface designed to control the movement of prosthetic limbs using magnetic beads positioned in the residual limb and external sensors. The new implant technology is designed to enable people using bionic prostheses to move as naturally and intuitively as possible.

Digital solution for sockets and liners

BionicSkins offers a digital fitting process for prosthetic sockets and liners. The innovative technology uses CT imaging, physics-based computation, AI, and 3D printing to guide clinicians in their mission to provide highly functional and comfortable prostheses – saving time and reducing frustration for patients and clinicians alike.